Related Experiment Video

Updated: Jun 16, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk

Jeroen B van der Net1, Daniëlla M Oosterveer, Jorie Versmissen

  • 1Department of Internal Medicine, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands.

European Heart Journal
|July 5, 2008
PubMed

Insights

This study replicated genetic associations with coronary heart disease (CHD) in familial hypercholesterolemia (FH) patients. Four genetic polymorphisms were confirmed to be associated with CHD risk in this high-risk population.

Area of Science:

  • Cardiovascular Genetics
  • Human Genetics
  • Genomics

Background:

  • Large association studies have identified genetic polymorphisms linked to myocardial infarction and coronary heart disease (CHD).
  • Individuals with familial hypercholesterolemia (FH) have an extremely high risk of CHD, making them a crucial population for genetic studies.
  • Replication of genetic findings in diverse populations is essential for validating their clinical relevance.

Purpose of the Study:

  • To replicate previously identified genetic associations with CHD in a large cohort of FH patients.
  • To assess the predictive value of specific genetic polymorphisms in individuals at high risk for CHD.
  • To identify genetic markers that could aid in the early prediction of CHD in FH individuals.

Main Methods:

  • Genotyping of 10 selected polymorphisms in 2145 FH patients.
  • Utilizing Cox proportional hazards models to analyze the association between polymorphisms and CHD.
  • Statistical analysis to confirm or refute previously reported genetic associations.

Main Results:

  • Confirmed associations between four polymorphisms and CHD risk: rs1151640 (OR13G1), rs11881940 (HNRPUL1), rs3746731 (CD93), and rs10757274 (near CDKN2A/B).
  • Hazard ratios ranged from 1.14 to 1.39, with statistically significant p-values for the confirmed associations.
  • Refuted associations for six other polymorphisms in the FH population.

Conclusions:

  • Replication confirmed four genetic polymorphisms associated with CHD in FH patients.
  • Six previously reported associations were not replicated in this high-risk FH cohort.
  • Emphasizes the critical need for replication studies before integrating genetic information into CHD risk prediction models.
Abstract

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...